REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call provided mixed signals. Basic financial performance showed a slight decrease in cash reserves but stable revenue. Product development updates were positive, especially for RGX-202 and RGX-121, but lacked immediate catalysts. Market strategy and expenses were neutral, with ongoing trials and collaborations. The Q&A revealed management's cautious optimism but also uncertainty in regulatory timelines. The sentiment is neutral overall, as the long-term potential is balanced by short-term uncertainties and lack of immediate positive catalysts.
Key Financial Performance
Cash, Cash Equivalents, and Marketable Securities $241 million as of December 31, 2025, compared to $245 million as of December 31, 2024. The decrease reflects the $110 million upfront payment from Nippon Shinyaku and $145 million in net proceeds from royalty monetization offset by cash used for operating activities.
R&D Expenses $228 million for the year ended December 31, 2025, compared to $209 million in 2024. The increase is attributed to pivotal trial execution and manufacturing of RGX-202 and sura-vec.
Total Annual Revenue $170 million for 2025. This includes upfront license revenue from the Nippon Shinyaku collaboration and increased royalty revenue for Zolgensma and other products.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RGX-202 for Duchenne muscular dystrophy: Momentum remains strong with completed dosing in pivotal study and robust enrollment in confirmatory trial. Phase I/II data show meaningful differentiation and favorable safety profile. BLA submission planned for 2026.
Sura-vec for wet AMD: Enrollment completed in pivotal studies ATMOSPHERE and ASCENT. Top-line data expected in Q4 2026. If approved, it would be the first gene therapy for wet AMD.
Sura-vec for diabetic retinopathy: NAVIGATE pivotal study initiated with first patient dosing expected next quarter, triggering a $100 million milestone from AbbVie.
Global Duchenne muscular dystrophy market: Less than 1% of the global Duchenne population has received approved gene therapy, highlighting significant unmet need.
Wet AMD and diabetic retinopathy market: Sura-vec represents a potential first-in-class gene therapy for these indications, addressing large global markets.
Financial position: Ended 2025 with $241 million in cash and equivalents. Cash runway expected to fund operations into early 2027, potentially extended to late 2027 with milestones.
R&D investment: R&D expenses increased to $228 million in 2025, focused on pivotal trials and manufacturing for RGX-202 and sura-vec.
Partnership with AbbVie: Collaboration on sura-vec for diabetic retinopathy and wet AMD progressing, with significant milestones expected.
Manufacturing capabilities: Investment in in-house manufacturing to support commercialization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Product Development Risks: Forward-looking statements regarding financial outlook, regulatory, and product development plans are subject to risks and uncertainties. Clinical holds for RGX-111 and RGX-121 require addressing specific requirements to proceed. The company is working on a CRL response and a type A meeting for resubmitting the BLA for RGX-121.
Clinical Trial and Safety Risks: The RGX-111 study reported a serious adverse event (SAE) involving AAV vector genome integration, which contributed to tumor formation. This raises concerns about the safety profile of the therapy. Additionally, the company is addressing clinical holds for RGX-111 and RGX-121.
Market and Commercialization Risks: The company is transitioning from a late-stage development organization to a commercial entity, which involves significant execution risks. There is also uncertainty in achieving FDA approval for RGX-202 and sura-vec, which are critical for the company's commercial success.
Financial Risks: The company reported a cash balance of $241 million as of December 31, 2025, which is expected to fund operations into early 2027. However, this guidance excludes potential revenue from MPS programs and additional funds from agreements, creating financial uncertainty.
Manufacturing and Supply Chain Risks: The company is investing in in-house manufacturing capabilities, which could face challenges in scaling up production to meet commercial demand, especially for RGX-202 and sura-vec.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
RGX-202 for Duchenne Muscular Dystrophy: Momentum remains strong with completed dosing in the pivotal study and robust enrollment in the confirmatory trial. Top-line data from the pivotal study is expected early in Q2 2026, with a BLA submission planned using the accelerated approval pathway. By fall 2026, 12-month functional data on the majority of pivotal trial patients will be available.
Sura-vec for Wet AMD: Top-line data from the pivotal ATMOSPHERE and ASCENT studies are expected in Q4 2026. If approved, sura-vec would be the first gene therapy for wet AMD.
Sura-vec for Diabetic Retinopathy: Site activation for the NAVIGATE pivotal study is underway, with first patient dosing expected next quarter. This will trigger a $100 million milestone from AbbVie. The Phase IIb portion will enroll 136 patients, with a primary endpoint of 2-step or greater improvement on the DRSS at 1 year.
MPS Programs (RGX-111 and RGX-121): Efforts are ongoing to address clinical holds and resubmit the BLA for RGX-121. A type A meeting with the FDA is planned.
Financial Guidance: Cash runway is expected to fund operations into early 2027, excluding a $100 million milestone from AbbVie and additional funds from the Healthcare Royalty agreement, which could extend the runway into the second half of 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives you confidence on your path to accelerated approval and on the design of your confirmatory study for DMD?
A:The protocol was prospectively reviewed by the FDA, and the design and stats plan were approved without changes. The data shows compelling results, especially in older patients, and the confirmatory study was included in the original protocol and reviewed by the FDA. Enrollment in the confirmatory study has been strong, increasing the safety database to roughly 50 total exposures. The data shows improved safety and efficacy, which aligns with FDA's requirements for accelerated approval.
Q:When did the discussions with the FDA regarding the confirmatory study protocol take place, and under which leadership?
A:The discussions took place under the prior FDA leadership, around 2024. The review team involved in those discussions remains largely intact.
Q:What would be the implications if the FDA requires longer-term follow-up for safety in the DMD program?
A:The pivotal study completed enrollment in October last year, so 12-month data on the full pivotal data set will be available this year. The confirmatory study is already enrolling, which will provide additional data. The company believes the data from the Phase I/II study already shows significant differences from natural history, and the safety profile is strong.
Q:What are your thoughts on the Denali approval decision and its impact on your Hunter program?
A:The Denali decision will be closely monitored, especially regarding the heparan sulfate-based biomarker. If the FDA endorses heparan sulfate, the company is prepared to pivot to that data. The company believes its D2S6 data shows strong biomarker reduction and is consistent across patients.
Q:Why are you moving forward with dose level 3 in the 314 program instead of dose level 4?
A:Dose level 3 showed compelling results, hitting the target product profile with durability and safety. The decision was made to move forward with dose level 3 as it met the desired outcomes, including a dramatic reduction in vision-threatening complications and no cases of IOI with short-course topical steroids.
Q:What is the status of the wet AMD program in light of the decision to move forward with dose level 3 in the 314 program?
A:The wet AMD program is more complex in terms of assessing efficacy compared to diabetic retinopathy. The company and AbbVie are continuing to evaluate the data for wet AMD.
Q:How much functional data will be provided in the top-line results for the DMD program?
A:The top-line results will include safety data for the full cohort (N=30), biomarker data for the primary endpoint, and functional data for approximately 7 patients at 12 months. Additional updates may be provided as more data becomes available.
Q:How does the neoplasm in the MPS I patient affect the benefit-risk discussion with the FDA?
A:The clinical community views the rare risk of a tumor as outweighed by the 100% risk of irreversible brain damage in untreated patients. Mitigation measures include periodic MRI, full disclosure in informed consent, and continued monitoring.
Q:What data will be presented at the MDA meeting for RGX-202?
A:The MDA meeting will include updates on functional data with more patients and longer follow-up, as well as preclinical data showing the differentiation of the construct in preventing cardiac deterioration. Safety data will also be updated.
Q:What is the regulatory strategy for RGX-202 in Europe?
A:The company is awaiting feedback on designs that include a placebo arm, which are feasible to run outside the U.S. Specific timelines for the European study have not been disclosed.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer on the specific timing of the BLA submission for RGX-202, stating that it depends on the outcomes of the pre-BLA meeting and ongoing discussions with the FDA. They also did not provide clarity on the exact regulatory path and timelines for European approval, stating that they are awaiting feedback from EMEA.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAV vector
ALTITUDE trial
BLA submission
CRL
DR
DRSS
Executive VP
Healthcare Royalty
II ALTITUDE
II study
NSAA
PLAG
Phase II
Phase IIb
VP Chief
activation
agreement
analysis
cTAP
date Phase
dosing
hold
line study
milestone AbbVie
momentum study
month majority
recipient
royalty monetization
set
stage program
study patient
sura vec
therapy program
today REGENXBIO
trial sura
tumor
vector integration
week
RGNX Transcript
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-22
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance with a 12% revenue increase and a 20% improvement in net loss, indicating efficient cost management. Product development progress is evident with RGX-202 top-line data release. Although strategic initiatives and shareholder returns were not discussed, the financial health and product advancements provide a positive outlook. Despite some risks, the overall sentiment is positive, likely resulting in a 2% to 8% stock price increase.
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call provided mixed signals. Basic financial performance showed a slight decrease in cash reserves but stable revenue. Product development updates were positive, especially for RGX-202 and RGX-121, but lacked immediate catalysts. Market strategy and expenses were neutral, with ongoing trials and collaborations. The Q&A revealed management's cautious optimism but also uncertainty in regulatory timelines. The sentiment is neutral overall, as the long-term potential is balanced by short-term uncertainties and lack of immediate positive catalysts.
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
RGNX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
